Brainstorm Cell Therapeutics (NASDAQ:BCLI) Now Covered by Analysts at StockNews.com

StockNews.com assumed coverage on shares of Brainstorm Cell Therapeutics (NASDAQ:BCLI) in a research report released on Saturday morning. The brokerage issued a hold rating on the biotechnology company’s stock.

Brainstorm Cell Therapeutics Stock Down 4.0 %

Brainstorm Cell Therapeutics stock opened at $1.66 on Friday. The stock has a 50-day moving average price of $2.02 and a 200 day moving average price of $2.53. The company has a market capitalization of $9.47 million, a price-to-earnings ratio of -0.35 and a beta of 0.26. Brainstorm Cell Therapeutics has a 52 week low of $1.05 and a 52 week high of $11.89.

About Brainstorm Cell Therapeutics

Brainstorm Cell Therapeutics Inc, a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function.